We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • Topics
  • CME
  • Special Reports
  • Slideshows
  • Quizzes
  • Blogs
  • Conferences
  • Classifieds
  • Archives

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • Topics
  • CME
  • Special Reports
  • Slideshows
  • Quizzes
  • Blogs
  • Conferences
  • Classifieds
  • Archives

SUBSCRIBE: eNewsletter

Adjunctive Metformin for Patients With Schizophrenia

  • Brian Miller, MD, PhD, MPH
Jan 5, 2017
  • Schizophrenia, Metabolic Disorders, Psychopharmacology
Antoshkaforever/Shutterstock

RESEARCH UPDATE

Antipsychotic treatment is associated with weight gain and metabolic syndrome, a constellation of metabolic risk factors associated with the development of atherosclerotic cardiovascular disease. Cardiovascular disease is the leading cause of death in patients with schizophrenia.1 The metabolic syndrome is common in patients with schizophrenia, with a prevalence of 43% in the Clinical Antipsychotic Trials of Intervention Effectiveness.2

Metformin is an anti-diabetic agent that enhances the action of insulin in the liver (and thereby decreases hepatic glucose production) and suppresses appetite. In addition to its use in type 2 diabetes mellitus, metformin is also used to treat obesity in persons who do not have diabetes by decreasing both insulin resistance and appetite. Metformin has been investigated for the treatment of antipsychotic-induced weight gain in several randomized controlled trials.

De Silva and colleagues3 conducted a meta-analysis of all randomized double-blind placebo-controlled trials of metformin in patients with DSM-IV, DSM-V, or ICD-10 schizophrenia or schizoaffective disorder. They performed a systematic search of the Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE.

Trials of metformin alone or metformin plus lifestyle intervention were included. Open-label trials and observational studies were excluded. The primary outcome measure was mean change in weight. Secondary outcomes were change in BMI, fasting glucose, and the insulin resistance index.

One hundred thirty-seven studies were screened, and 12 studies comprising 743 patients met the inclusion/exclusion criteria. In most studies, metformin was dosed at 1000 mg per day. Ten studies were performed in adults, and 2 studies included children and adolescents.

The authors found that metformin was associated with significantly greater absolute weight loss (-3.3 kg) and percentage weight loss (-5.0%) than placebo. Metformin was also associated with significantly greater reduction in BMI (-1.1 kg/m2) than placebo. Fasting glucose was non-significantly reduced (-2.5 mg/dL), but the insulin resistance index was significantly reduced (-1.5) in patients treated with adjunctive metformin. Rates of discontinuation and adverse events were low in both metformin and placebo groups.

In a subgroup analysis, the pattern of results was similar in studies of adults and children and adolescents, considered separately. Importantly, the effects of metformin on weight were greater in studies of patients with first-episode psychosis (-5.9 kg) than in those of patients with chronic illness (-2.1 kg).

The bottom line
The authors found evidence that adjunctive metformin was associated with significantly greater reductions in weight, BMI, and metabolic parameters than placebo during antipsychotic treatment in patients with schizophrenia or schizoaffective disorder. Findings suggest more robust effects of metformin earlier in the course of the disorder. They concluded that metformin should have more widespread use in patients with antipsychotic-induced weight gain.

Disclosures: 

Dr. Miller is Associate Professor in the Department of Psychiatry and Health Behavior at Augusta University in Augusta, GA, and Schizophrenia Section Editor for Psychiatric Times. He reports no conflicts of interest concerning the subject matter of this article.

References: 

1. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64:1123-1131.

2. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.

3. De Silva VA, Suraweera C, Ratnatunga SS, et al. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. BMC Psychiatry. 2016;16:341.

Related Articles

  • Lifestyle, Personality, and Metabolic Changes in the Elderly
  • Expert Q&A: Schizophrenia and Weight Gain
  • Metabolic Monitoring of Antipsychotic Medications: What Psychiatrists Need to Know
  • The Wandering Woman: A Pituitary Tumor
  • Treatment of Metabolic Risk Factors in Patients With Psychotic Disorders

Resource Topics rightRail

  • Resource Topics
  • Partner Content
ADHD
Schizophrenia
Bipolar Disorder
Geriatric Psychiatry
Major Depressive Disorder
Smart IOP – A New Kind of Intensive Outpatient Program
Three Things Mental Health Professionals Need to Know About Telemedicine – TODAY!
How Telemedicine Can Transform Patient Engagement

Current Issue

Psychiatric Times Vol 35 No 3
Mar 12, 2018 Vol 32 No 3
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • Google+
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.